The latest from NuvOx

Welcoming the New Kid on the Block; A Phase IIb Study of DDFPe in Large Vessel Strokes

The design for an efficient Phase IIb clinical trial in stroke to test DDFPe in patients with Large Vessel Occlusions.

This randomized, placebo-controlled, double-blind, dose-escalation clinical trial in acute ischemic stroke patients was designed to...

Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...

DDFPe reduces infarct volume and neurological function following anterior ischemic stroke.

DDFPe significantly extends the time window for tPA therapy.

DDFPe delays and reduces MRI markers of stroke in the early hours following vascular occlusion in a rat stroke model.

Increasing the number of DDFPe applications was significant in reducing the incidence of premature death.

DDFPe alleviates hypoxia in areas of ischemia.

DDFPe treatment provides significant neuroprotection when assessed six hours post stroke.

Intravenous DDFPe decreases ischemic stroke infarct volumes. Rapid development is warranted.

Intravenous DDFPe in an animal model decreases infarct volumes and protects brain tissue from ischemia justifying further investigation.